Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cody J Peer

Showing results (111-120 of 140) with videos related to

Pageof 14
Sort By:
Neuro-Oncology|August 1, 2023
Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047)Michelle Monje, Tabitha Cooney, John Glod, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2012
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemiaCody J Peer, Tristan M Sissung, Aerang Kim, et al.
The Journal of Clinical Investigation|June 26, 2018
HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancerMohammad Alyamani, Hamid Emamekhoo, Sunho Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2017
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I StudyJung-Min Lee, Ashley Cimino-Mathews, Cody J Peer, et al.
Frontiers in Cell and Developmental Biology|November 8, 2024
Treatment with novel topoisomerase inhibitors in Ewing sarcoma models reveals heterogeneity of tumor responseUnsun Lee, Ludmila Szabova, Victor J Collins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2017
Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular CarcinomaAustin G Duffy, Chi Ma, Susanna V Ulahannan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2019
IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset ExpansionKevin C Conlon, E Lake Potter, Stefania Pittaluga, et al.
Blood|March 1, 2011
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphomaRichard L Piekarz, Robin Frye, H Miles Prince, et al.
Plos One|March 29, 2016
Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C DiseaseElena-Raluca Nicoli, Nada Al Eisa, Celine V M Cluzeau, et al.
Molecular Pharmacology|June 9, 2019
Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile TransportersTristan M Sissung, Phoebe A Huang, Ralph J Hauke, et al.
Pageof 14

Showing results (111-120 of 140) with videos related to

Sort By:
Pageof 14
Neuro-Oncology|August 1, 2023
Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047)Michelle Monje, Tabitha Cooney, John Glod, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2012
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemiaCody J Peer, Tristan M Sissung, Aerang Kim, et al.
The Journal of Clinical Investigation|June 26, 2018
HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancerMohammad Alyamani, Hamid Emamekhoo, Sunho Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2017
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I StudyJung-Min Lee, Ashley Cimino-Mathews, Cody J Peer, et al.
Frontiers in Cell and Developmental Biology|November 8, 2024
Treatment with novel topoisomerase inhibitors in Ewing sarcoma models reveals heterogeneity of tumor responseUnsun Lee, Ludmila Szabova, Victor J Collins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2017
Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular CarcinomaAustin G Duffy, Chi Ma, Susanna V Ulahannan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2019
IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset ExpansionKevin C Conlon, E Lake Potter, Stefania Pittaluga, et al.
Blood|March 1, 2011
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphomaRichard L Piekarz, Robin Frye, H Miles Prince, et al.
Plos One|March 29, 2016
Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C DiseaseElena-Raluca Nicoli, Nada Al Eisa, Celine V M Cluzeau, et al.
Molecular Pharmacology|June 9, 2019
Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile TransportersTristan M Sissung, Phoebe A Huang, Ralph J Hauke, et al.
Pageof 14